Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression.
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression.
复制标题
DOI：
10.1016/j.ygyno.2011.12.446
复制
发表时间：
2012-04
影响因子：
4.7
通讯作者：
Santin AD
中科院分区：
文献类型：
--
作者：
Carrara L;Guzzo F;Roque DM;Bellone S;Emiliano C;Sartori E;Pecorelli S;Schwartz PE;Rutherford TJ;Santin AD
To compare the in vitro sensitivity/resistance to patupilone versus paclitaxel in uterine and ovarian carcinosarcomas (CS). Five primary carcinosarcoma cell lines, two from uterine and three of ovarian origin, were evaluated for growth rate and tested for their in vitro sensitivity/resistance to patupilone versus paclitaxel by MTS assays. To identify potential mechanisms underlying the differential sensitivity/resistance to patupilone, expression levels of β-tubulin III (TUBB3) were determined with quantitative-real-time-polymerase-chain-reaction (q-RT-PCR) in primary uterine and ovarian CS cell lines and in 26 uterine and 9 ovarian CS fresh-frozen-tissues. No appreciable difference in sensitivity to patupilone versus paclitaxel was noted in ovarian CS cell lines, or when uterine and ovarian CS cell lines were compared in their response to paclitaxel. In contrast, uterine CS cell lines were found to be significantly more sensitive to patupilone than to paclitaxel (P < 0.002) and demostrated lower IC50s to patupilone (range 0.76–0.93 nM) when compared to ovarian CS (range 1.9–3.4 nM, P < 0.05). Higher levels of TUBB3 were detected in uterine CS cell lines and fresh frozen tissues when compared to ovarian CS (P< 0.05). Uterine CS cell lines are significantly more sensitive than ovarian CS cell lines to patupilone versus paclitaxel. High expression of TUBB3 is associated with sensitivity to patupilone in primary CS cell lines and may act as a genetic marker to predict chemotherapy efficacy. Patupilone may represent a promising drug in the treatment of this subset of rare but highly aggressive gynecological tumors.
登录
查看更多内容
影响因子：
45.3
作者：
Dizon, Don S.;Blessing, John A.;Alvarez, Ronald D.
通讯作者：
Alvarez, Ronald D.
影响因子：
11.5
作者：
Sève, P;Isaac, S;Dumontet, C
通讯作者：
Dumontet, C
影响因子：
8.8
作者：
通讯作者：
--
DOI：
10.1016/s0006-291x(02)00269-3
发表时间：
2002-04-26
影响因子：
3.1
作者：
Banerjee, A
通讯作者：
Banerjee, A
DOI：
10.1097/pgp.0b013e318156c838
发表时间：
2008-04-01
影响因子：
2.4
作者：
Umezu, Tomokazu;Shibata, Kiyosumi;Kikkawa, Fumitaka
通讯作者：
Kikkawa, Fumitaka